免疫组股份公司美股招股说明书(2025-12-15版)

Our common stock is traded on the Nasdaq Capital Market under the symbol “IMNM.” On December15, 2025, the last reportedsale price of our common stock on the Nasdaq Capital Market was $22.64 per share. The final public offering price will bedetermined through negotiation between us and the lead underwriters in the offering and the recent market price used throughout We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012 and a “smallerreporting company” as defined under the federal securities laws and, as such, have elected to comply with certain reduced publiccompany disclosure and reporting requirements. (1)See “Underwriting” for a description of the compensation payable to the underwriters. Clay Siegall, our Chief Executive Officer and Chairman of the Board, has indicated an interest in purchasing up to an aggregateof approximately $1,000,000 of the shares of our common stock offered by us in this offering at the public offering price.However, because indications of interest are not binding agreements or commitments to purchase, the underwriters maydetermine to sell more, fewer or no shares of our common stock in this offering to him, or he may determine to purchase more, We have granted the underwriters an option to purchase up to an additional $60,000,000 of shares of our common stock from usat the public offering price, less underwriting discounts and commissions, within 30 days from the date of this prospectus Investing in our common stock involves a high degree of risk. You should review carefully the risks anduncertainties described under the heading “Risk factors” of this prospectus supplement and in the documentsincorporated by reference into this prospectus supplement and the accompanying prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Anyrepresentation to the contrary is a criminal offense. The underwriters expect to deliver the shares of our common stock to purchasers on or aboutLeerinkPartnersJ.P.MorganTDCowen GuggenheimSecurities The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating tothese securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplementand the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities inany jurisdiction where the offer or sale is not permitted.Co-Lead Managers WedbushPacGrow Table of Contents TABLE OF CONTENTS Prospectus supplement PageS-iiS-1S-3S-5S-7S-9 About this prospectus supplementProspectus supplement summaryThe offeringRisk factors Prospectus ii16789 Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock and also adds toand updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement andthe accompanying prospectus. The second part, the accompanying prospectus dated February13, 2024, including the documents incorporated byreference therein, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this documentcombined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information We have not, and the underwriters have not, authorized anyone to provide any information other than that contained or incorporated by reference in thisprospectus supplement, the accompanying prospectus or in any free writing prospectus that we have authorized for use in connection with this offering.We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.The information contained in this prospectus supplement, the accompanying prospectus, any free writing prospectus that we have authorized for use inconnection with this offering, including the documents incorporated by reference herein or therein, is accurate only as of the respective dates thereof,regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our common stock. It is important for We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions in which offers and sales arepermitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictionsmay be restricted by law. Persons outside the United States who come into possession of thi